Ert Pompe denied as not medically necessary by Humana?

Humana's specific coverage criteria for ert pompe are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Pompe Disease ERT on Medical-Necessity Grounds — and How to Build Your Appeal

Medical-necessity denials for enzyme replacement therapy in Pompe disease typically occur when Humana's clinical reviewer determines that the submitted documentation does not sufficiently establish that the patient meets the coverage criteria in Humana's medical policy. Common gaps include insufficient documentation of disease severity, absent or incomplete genetic or enzymatic confirmation of diagnosis, or a prescriber letter that describes the drug rather than explaining why this specific patient requires it now.

This denial is not a judgment that ERT cannot work for Pompe disease — it is a determination that the record as submitted did not prove the patient's eligibility under the policy's criteria. That means the appeal is a documentation exercise: assemble the evidence the reviewer needed and present it directly against each policy requirement.

## Federal Appeal Rights

Humana plans subject to ACA Section 2719 must provide internal appeal and, if the internal appeal is denied, access to independent external review. ERISA Section 503 applies to employer-sponsored plans and guarantees access to the specific clinical criteria and reviewer rationale. The external review window is generally four months from the final internal adverse determination. An expedited track is available when delay would seriously jeopardize the patient's health or ability to regain maximum function.

## What to Gather

• Diagnosis confirmation — the definitive diagnostic evidence for the patient's Pompe disease (enzyme-activity assay results, genetic testing identifying the causative variant, or muscle biopsy findings, depending on what Humana's policy specifies).
• Disease severity documentation — pulmonary function test trends, six-minute walk test results, motor function assessments, and any documentation of respiratory insufficiency or ambulatory decline from the clinical record.
• Prior-treatment history — dates and outcomes of any prior management, including what was tried, when, and why ERT is now indicated.
• Prescriber medical-necessity letter — the physician's letter should address each criterion in Humana's policy by name, provide the corresponding chart fact, and explain the clinical reasoning linking the patient's documented status to the need for ERT.
• Humana's current coverage policy — download the policy from Humana's online policy library and identify every required criterion.

## Criteria-Mapping Structure

Create a structured table: left column reproduces each medical-necessity criterion from Humana's policy verbatim; right column provides the specific chart finding, test result, or prescriber statement that satisfies it. For any criterion where documentation is thin, obtain supplemental records or a physician attestation before filing. An appeal that leaves any policy criterion unanswered gives the reviewer a reason to deny again.

## Process and Timeline

1. Request the complete clinical-review rationale and the specific policy version used — you are entitled to these before filing. 2. Submit the written internal appeal within the plan's deadline, with all documentation organized per the criteria table. 3. If denied internally, file for external review within four months. 4. Consider the expedited track for patients experiencing measurable decline.